Combined hemodialysis-hemoperfusion in the treatment of secondary hyperparathyroidism of uremic patients.

Clinical review 20: Recent advances in the pathogenesis and therapy of uremic secondary hyperparathyroidism.

Role of surgery in the treatment of renal secondary hyperparathyroidism.

Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.

Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.

Thyroid carcinoma in patients with secondary hyperparathyroidism.

A new paradigm for the treatment of secondary hyperparathyroidism.

Hemodialysis patients' preferences for the management of secondary hyperparathyroidism.

Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients.

Effect of cinacalcet treatment on vascular arterial stiffness among peritoneal dialysis patients with secondary hyperparathyroidism.

Skeletal findings in secondary hyperparathyroidism.

Racial differences in secondary hyperparathyroidism.

Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.

Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol.

The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review.

Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study.

Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study.

The optimal timing of hemoperfusion component in combined hemodialysis-hemoperfusion treatment for uremic toxins removal.

Secondary hyperparathyroidism: diagnosis of site of recurrence.

The importance of prevention of calciphylaxis in patients who are at risk and the potential fallibility of calcimimetics in the treatment of calciphylaxis for patients with secondary hyperparathyroidism.

The effect of parathyroidectomy on patient survival in secondary hyperparathyroidism.

PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism.

Brown tumor and secondary hyperparathyroidism.

Reply to "Imaging secondary hyperparathyroidism".

Diagnosis of primary and secondary hyperparathyroidism.

Suggest Documents

Clinical review 20: Recent advances in the pathogenesis and therapy of uremic secondary hyperparathyroidism.

Role of surgery in the treatment of renal secondary hyperparathyroidism.

Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.

Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.

Thyroid carcinoma in patients with secondary hyperparathyroidism.

A new paradigm for the treatment of secondary hyperparathyroidism.

Hemodialysis patients' preferences for the management of secondary hyperparathyroidism.

Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients.

Effect of cinacalcet treatment on vascular arterial stiffness among peritoneal dialysis patients with secondary hyperparathyroidism.

Skeletal findings in secondary hyperparathyroidism.

Racial differences in secondary hyperparathyroidism.

Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.

Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol.

The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review.

Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study.

Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study.

The optimal timing of hemoperfusion component in combined hemodialysis-hemoperfusion treatment for uremic toxins removal.

Secondary hyperparathyroidism: diagnosis of site of recurrence.

The importance of prevention of calciphylaxis in patients who are at risk and the potential fallibility of calcimimetics in the treatment of calciphylaxis for patients with secondary hyperparathyroidism.

The effect of parathyroidectomy on patient survival in secondary hyperparathyroidism.

PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism.

Brown tumor and secondary hyperparathyroidism.

Reply to "Imaging secondary hyperparathyroidism".

Diagnosis of primary and secondary hyperparathyroidism.

Combined hemodialysis-hemoperfusion in the treatment of secondary hyperparathyroidism of uremic patients.

Recommend Documents

Follow Us